Researchers have made predictions as to how the tuberculosis (TB) epidemic in Peru might progress over the next 30 years, depending on what measures are used to fight it. They considered the five different approaches to treating drug-resistant TB that are open to the Peruvian health authorities.
TB is a growing problem worldwide. Most cases can be treated effectively with a standard treatment (known as 'DOTS', which stands for 'Directly Observed Therapy Short-Course') but an increasing number of cases are resistant to all the various 'first-line' treatment drugs; this is known as multi-drug resistant (MDR) TB. MDR-TB must be treated with 'second-line' drugs. There are several different options; for example, doctors could give second-line drugs whenever a first attempt at treatment has failed, or only use these drugs in cases where tests have confirmed MDR-TB to be the problem. MDR-TB cases could all be given the same standard treatment or, based on tests, each could have 'individualized' treatment.
The researchers used a method called 'modelling'. They performed calculations based on information already available about TB in Peru, where there are 120 new TB infections per 100,000 people every year and 4.5% of existing cases have MDR-TB. They concluded that use of second-line drugs would be cost-effective for Peru and that, despite the extra costs of individualized treatment, this is the best option. The results will be of interest in other developing countries. The researchers say, "In other settings, the attractiveness of strategies using second-line drugs will depend on TB incidence, MDR burden, and the available budget, but simulation results suggest that individualized regimens would be cost-effective in a wide range of situations". They also stress it is important for the standard first-line DOTS treatment to be made widely available.
PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.
All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
Citation: Resch SC, Salomon JA, Murray M, Weinstein MC (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3(7): e241.
PLEASE ADD THE LINKS TO THE PUBLISHED ARTICLES IN ONLINE
VERSIONS OF YOUR REPORT: http://dx.doi.org/10.1371/journal.pmed.0030241
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-07-resch.pdf
Harvard School of Public Health
Health Policy and Management
718 Huntington Ave
Boston, MA 02115 United States of America
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.